VASCO study: A population-based prospective cohort study on vaccine effectiveness of COVID-19 vaccines in the Netherlands

VASCO study: A population-based prospective cohort study on vaccine effectiveness of COVID-19 vaccines in the Netherlands - VASCO study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON55915

Enrollment

50000

Registered

2021-02-15

Start date

2021-05-05

Completion date

Unknown

Last updated

2026-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

corona COVID-19 SARS-CoV-2 infection Corona

Interventions

None

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Community dwelling adult between 18-84 years - Informed consent provided - Be able to read, understand and write Dutch

Exclusion criteria

Exclusion criteria: - Not able or willing to understand and sign the informed consent - Not able to fill out a digital (app) questionnaire - Persons living in an institution (e.g. elderly care home, nursing home)

Design outcomes

Primary

Measure	Time frame
The primary endpoint is symptomatic SARS-CoV-2 infection, determined by a positive PCR or antigen test in combination with COVID-19 related symptoms.	—

Secondary

Measure	Time frame
Secondary endpoints are SARS-CoV-2 infections by disease severity and unsolicited adverse events of special interest following vaccination.	—

Countries

Netherlands

Contacts

Public ContactM.J. Knol

RIVM

info@rivm.nl088 689 8989

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP) · Data processed: May 22, 2026